TherapeuticsMD, Inc. Files Amendment No. 1 to Annual Report on Form 10-K
Ticker: TXMD · Form: 10-K/A · Filed: Apr 29, 2024 · CIK: 25743
Sentiment: neutral
Topics: 10-K/A, Amendment, SEC Filing, TherapeuticsMD, TXMD
TL;DR
<b>TherapeuticsMD, Inc. has filed an amendment to its 2023 annual report, confirming compliance with SEC filing requirements.</b>
AI Summary
TherapeuticsMD, Inc. (TXMD) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. TherapeuticsMD, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Nevada and its principal executive offices are located in Boca Raton, Florida. Its common stock trades on The Nasdaq Stock Market LLC under the ticker symbol TXMD. TherapeuticsMD, Inc. has confirmed it has filed all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days. The company has submitted electronically every Interactive Data File required by Rule 405 of Regulation S-T during the preceding 12 months.
Why It Matters
For investors and stakeholders tracking TherapeuticsMD, Inc., this filing contains several important signals. This amendment indicates that TherapeuticsMD is actively managing its reporting obligations, which is crucial for maintaining investor confidence and regulatory compliance. The confirmation of electronic filing of Interactive Data Files suggests adherence to modern disclosure standards, important for data analysis and accessibility by investors and analysts.
Risk Assessment
Risk Level: low — TherapeuticsMD, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, suggesting it's a procedural update rather than a material event, thus posing low immediate risk.
Analyst Insight
Monitor future filings for any substantive changes or disclosures that may arise from this amendment.
Key Numbers
- 20231231 — Fiscal Year End (Conformed period of report)
- 20240429 — Filing Date (Filed as of date)
- 001-00100 — Commission File Number (SEC File Number)
- 2834 — Standard Industrial Classification (Pharmaceutical Preparations)
Key Players & Entities
- TherapeuticsMD, Inc. (company) — Registrant
- TXMD (company) — Trading symbol
- The Nasdaq Stock Market LLC (company) — Name of each exchange on which registered
- Nevada (company) — State of incorporation
- Boca Raton (company) — City of principal executive offices
- Florida (company) — State of principal executive offices
- 33431 (dollar_amount) — ZIP code of principal executive offices
- 561-961-1900 (dollar_amount) — Business phone number
FAQ
When did TherapeuticsMD, Inc. file this 10-K/A?
TherapeuticsMD, Inc. filed this Amended Annual Report (10-K/A) with the SEC on April 29, 2024.
What is a 10-K/A filing?
A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by TherapeuticsMD, Inc. (TXMD).
Where can I read the original 10-K/A filing from TherapeuticsMD, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by TherapeuticsMD, Inc..
What are the key takeaways from TherapeuticsMD, Inc.'s 10-K/A?
TherapeuticsMD, Inc. filed this 10-K/A on April 29, 2024. Key takeaways: TherapeuticsMD, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023.. The company is incorporated in Nevada and its principal executive offices are located in Boca Raton, Florida.. Its common stock trades on The Nasdaq Stock Market LLC under the ticker symbol TXMD..
Is TherapeuticsMD, Inc. a risky investment based on this filing?
Based on this 10-K/A, TherapeuticsMD, Inc. presents a relatively low-risk profile. The filing is an amendment to a 10-K, suggesting it's a procedural update rather than a material event, thus posing low immediate risk.
What should investors do after reading TherapeuticsMD, Inc.'s 10-K/A?
Monitor future filings for any substantive changes or disclosures that may arise from this amendment. The overall sentiment from this filing is neutral.
How does TherapeuticsMD, Inc. compare to its industry peers?
TherapeuticsMD operates in the pharmaceutical preparations industry, focusing on women's healthcare.
Are there regulatory concerns for TherapeuticsMD, Inc.?
The filing is an amendment to a Form 10-K, subject to the regulations of the Securities Exchange Act of 1934.
Industry Context
TherapeuticsMD operates in the pharmaceutical preparations industry, focusing on women's healthcare.
Regulatory Implications
The filing is an amendment to a Form 10-K, subject to the regulations of the Securities Exchange Act of 1934.
What Investors Should Do
- Review the full 10-K/A filing for any specific details or corrections made in the amendment.
- Track TherapeuticsMD's ongoing SEC filings for future disclosures.
- Analyze the company's financial health and strategic direction based on its complete annual reporting.
Year-Over-Year Comparison
This filing is an amendment (10-K/A) to the previous 10-K filing for the fiscal year ended December 31, 2023.
Filing Stats: 4,559 words · 18 min read · ~15 pages · Grade level 12.4 · Accepted 2024-04-29 17:00:17
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Market
Filing Documents
- ea0204829-10ka1_therapeu.htm (10-K/A) — 370KB
- ea020482901ex31-1_therapeu.htm (EX-31.1) — 4KB
- ea020482901ex31-2_therapeu.htm (EX-31.2) — 3KB
- image_001.jpg (GRAPHIC) — 8KB
- 0001213900-24-037258.txt ( ) — 665KB
- txmd-20231231.xsd (EX-101.SCH) — 3KB
- txmd-20231231_def.xml (EX-101.DEF) — 17KB
- txmd-20231231_lab.xml (EX-101.LAB) — 34KB
- txmd-20231231_pre.xml (EX-101.PRE) — 18KB
- ea0204829-10ka1_therapeu_htm.xml (XML) — 7KB
Executive Compensation
Executive Compensation 10 Item 12.
Security Ownership of Certain Beneficial
Security Ownership of Certain Beneficial 16 Item 13. Certain Relationships and Related Transactions, and Director Independence 18 Item 14. Principal Accountant Fees and Services 19 Part IV Item 15. Exhibits and Financial Statement Schedules 20
Signatures
Signatures 24 i PART III Item 10. Directors, Executive Officers and Corporate Governance Directors The following table sets forth certain information regarding the current directors of the Company. Name Age Position Tommy G. Thompson 81 Chairman of the Board (2) Cooper C. Collins 44 Director (1)(2) Gail K. Naughton, Ph.D. 68 Director (1) Justin H. Roberts 41 Director (1)(2) (1) Member of the Compensation Committee. (2) Member of the Audit Committee. 1 TOMMY G. THOMPSON Chairman of the Board Director Since: 2012 Age: 81 Committee: Audit Biographical Information Tommy G. Thompson has served as a director of our company since May 2012 and as the Chairman of the Board of Directors since March 2024. He previously served as the Chairman of the Board of Directors from May 2012 until September 2022 and as Executive Chairman of the Board from September 2022 until March 2024. From July 2020 until March 2022, Secretary Thompson served as the Interim President of the University of Wisconsin system. Secretary Thompson also serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding healthcare access across all segments of society. As the former Secretary of the U.S. Department of Health & Human Services, or HHS, from February 2001 to January 2005, Secretary Thompson served as the nation's leading advocate for the health and welfare of all Americans. Secretary Thompson was a partner in the law firm of Akin Gump Strauss Hauer & Feld LLP, or Akin Gump, from March 2005 to January 2012, when he resigned to run for the United States Senate. Secretary Thompson served as an Independent Chairman of the Deloitte Center for Health Solutions, a healthcare consulting company,